10x Genomics Expands Gene Expression Flex Offering with New High-Throughput Multiomic Profiling Kit

Strengthen cellular analysis with cost-efficient multiomic readouts and streamlined workflows

PLEASANTON, Calif., Sept. 14, 2023 /PRNewswire/ -- 10x Genomics, Inc. (Nasdaq: TXG), a leader in single cell and spatial biology, announced today the commercial availability of a new kit to expand the capabilities of its Chromium Single Cell Gene Expression Flex assay to include high-throughput multiomic cellular profiling. The new kit enables streamlined, multiomic characterization of cell populations so that researchers can expand their options at a larger scale and detect simultaneous gene and protein expression.

"We're building on the momentum and enthusiasm for Chromium Flex by enabling researchers to gain more insights from a single experiment at scale," said Ben Hindson, Co-founder and Chief Scientific Officer at 10x Genomics. "With this latest launch, multiomic million-cell experiments are now accessible at a fraction of the cost."

The new Feature Barcode Multiplexing kit is part of the company's Chromium Single Cell Gene Expression Flex portfolio, which enables researchers to: 

• Fix and store samples without losing data quality, letting scientists run samples later and simplify transport
• Detect proteins at single cell resolution with workflows that enable small- to large-scale studies
• Batch and scale to profile up to 1M cells in a single run and save up to 75% on per-sample costs
• Bring scRNA-seq with industry-leading sensitivity to fresh, frozen or fixed tissue – even FFPE

"Single cell technologies have been transformative for our understanding of human health and disease," said Peter Skene, Director of High Resolution Translational Immunology at the Allen Institute. "Historically, single cell multi-omics have only profiled 1000s of cells per experiment, limiting the depth and breadth of questions that can be answered. New highly multiplexed single cell technologies, such as 10x Genomics Flex protein multiplex, allow the simultaneous measurement of RNA and protein from millions of cells at a significantly lower cost point. This is a game changer for the research community and will expand opportunities and impact for human health."  

The new Feature Barcode Multiplexing Kit is now shipping.

About 10x Genomics
10x Genomics is a life science technology company building products to accelerate the mastery of biology and advance human health. Our integrated solutions include instruments, consumables and software for single cell and spatial biology, which help academic and translational researchers and biopharmaceutical companies understand biological systems at a resolution and scale that matches the complexity of biology. Our products are behind breakthroughs in oncology, immunology, neuroscience and more, fueling powerful discoveries that are transforming the world's understanding of health and disease. To learn more, visit 10xgenomics.com or connect with us on LinkedIn or X (Twitter).

Forward Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 as contained in Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, which are subject to the "safe harbor" created by those sections. All statements, other than statements of historical facts, may be forward-looking statements. Forward-looking statements generally can be identified by the use of forward-looking terminology such as "may," "might," "will,""enable," "should," "expect," "plan," "anticipate," "could," "intend," "target," "project," "contemplate," "believe," "estimate," "predict," "potential," "would," "likely," "seek" or "continue" or the negatives of these terms or variations of them or similar terminology, but the absence of these words does not mean that a statement is not forward-looking. These forward-looking statements include statements regarding 10x Genomics, Inc.'s expectations regarding the continued growth and expansion of our Chromium platform, its performance and our product momentum and progress. These statements are based on management's current expectations, forecasts, beliefs, assumptions and information currently available to management, and actual outcomes and results could differ materially from these statements due to a number of factors. The material risks and uncertainties that could affect 10x Genomics, Inc.'s financial and operating results and cause actual results to differ materially from those indicated by the forward-looking statements made in this press release include those discussed under the captions "Risk Factors" and "Management's Discussion and Analysis of Financial Condition and Results of Operations" in the company's most recently-filed 10-K and elsewhere in the documents 10x Genomics, Inc. files with the Securities and Exchange Commission from time to time.

Although 10x Genomics, Inc. believes that the expectations reflected in the forward-looking statements are reasonable, it cannot provide any assurance that these expectations will prove to be correct nor can it guarantee that the future results, levels of activity, performance and events and circumstances reflected in the forward-looking statements will be achieved or occur. These forward-looking statements do not reflect the potential impact of any future acquisitions, mergers, dispositions, joint ventures or investments 10x Genomics, Inc. may make. Further, such forward-looking statements may not accurately or fully reflect the potential impact of adverse geopolitical and macroeconomic events, product capabilities and adoption rates, international economic, political, legal, compliance, social and business factors, such as the COVID-19 pandemic, inflation, supply chain that may have on the business, financial condition, results of operations and cash flows of 10x Genomics, Inc. The forward-looking statements in this press release are based on information available to 10x Genomics, Inc. as of the date hereof, and 10x Genomics, Inc. disclaims any obligation to update any forward-looking statements provided to reflect any change in our expectations or any change in events, conditions, or circumstances on which any such statement is based, except as required by law. These forward-looking statements should not be relied upon as representing 10x Genomics, Inc.'s views as of any date subsequent to the date of this press release.

Disclosure Information
10x Genomics, Inc. uses filings with the Securities and Exchange Commission, our website (www.10xgenomics.com), press releases, public conference calls, public webcasts and our social media accounts as means of disclosing material non-public information and for complying with our disclosure obligations under Regulation FD.

Contacts
Investors: investors@10xgenomics.com
Media: media@10xgenomics.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/10x-genomics-expands-gene-expression-flex-offering-with-new-high-throughput-multiomic-profiling-kit-301928498.html

SOURCE 10x Genomics, Inc.